TG Therapeutics, Inc.
TGTX
Positions held
Your positionsTGTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- TG Therapeutics is well-positioned in the biotechnology industry with a strong pipeline and a recommendation of 'strong buy', indicating investor confidence.
- Revenue increased by 17% compared to the prior quarter, reaching $240 million.
- The company maintains a gross margin of 82.9%, demonstrating efficient cost management.
- The operating margin has compressed to 9%, raising concerns about profitability.
- Earnings growth has declined significantly, with a decrease of 70.6% year-over-year.
- The stock has a high beta of 1.799, indicating greater volatility compared to the market.
Fundamentals
| Market cap | $8.17B | Enterprise value | $7.77B | Trailing P/E | 19.40 | Forward P/E | 19.70 |
| PEG | 1.61 | Price / book | 12.97 | Beta | 1.80 | Dividend yield | 0.00% |
| Revenue growth | 70.3% | Earnings growth | -70.6% | Gross margin | 82.4% | Operating margin | 9.0% |
| Profit margin | 55.2% | ROE | 100.3% | ROA | 7.3% | Debt / equity | 1.25 |
| Current ratio | 4.27 | Free cash flow | $59.13M | Analyst recommendation | strong_buy | Mean target | $69.71 |
| 52w high | $59.30 | 52w low | $26.76 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $240M | $205M | $193M | $162M | $141M | — |
| Op margin | 9.0% | 17.0% | 26.2% | 18.2% | 24.7% | — |
| Net income | $7.8M | $19.8M | $23.0M | $391M | $28.2M | — |
| Gross margin | 82.9% | 83.6% | 80.2% | 82.6% | 86.6% | — |
| Gross profit | $199M | $171M | $154M | $134M | $122M | — |
| Operating income | $21.7M | $34.8M | $50.5M | $29.4M | $34.8M | — |
- Revenue +17% vs prior quarter ($240M vs $205M).
- Gross margin 82.9% (was 83.6% prior quarter).
- Operating margin compressed to 9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $616M | $329M | $234M | $2.8M | — |
| Op margin | 20.0% | 12.7% | 8.8% | -7839.0% | — |
| Net income | $447M | $23.4M | $12.7M | -$224M | — |
| Gross margin | 83.7% | 88.3% | 94.0% | 90.5% | — |
| Gross profit | $516M | $291M | $220M | $2.5M | — |
| Operating income | $123M | $41.9M | $20.6M | -$218M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment Story
2026-10-09 · TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow
2026-10-08 · TG Therapeutics (TGTX) Just Sparked A Bigger Question
2026-10-08 · TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
2026-09-23 · Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
2026-09-18 · TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share
2026-09-18 · TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound
2026-09-17 · Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
2026-09-17 · Dow Jones Futures Rise After Hawkish Fed, Warsh Hit Stocks, Trump Fumes; AMD, Bloom Energy Eye Buy Points
2026-09-16 · TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry
2026-09-10 · TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-04 · Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Price (daily)
Full chart · RSI · MACD · patterns